Metrics to compare | MNOV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMNOVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.0x | −1.8x | −0.4x | |
PEG Ratio | 1.18 | −0.07 | 0.00 | |
Price/Book | 1.8x | 2.5x | 2.6x | |
Price / LTM Sales | 117.6x | 12.4x | 3.0x | |
Upside (Analyst Target) | - | 158.5% | 49.1% | |
Fair Value Upside | Unlock | 5.9% | 6.3% | Unlock |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.